Bayer, J&J’s Xarelto Prevented Repeat Strokes in Analysis

Bayer AG and Johnson & Johnson’s blood-thinner Xarelto was effective in preventing repeat strokes in an analysis of high-risk patients from the Rocket-AF trial, Bayer said today in a study presented at the European Stroke Conference in Hamburg, Germany.

Patients who took Xarelto, known chemically as rivaroxaban, showed a 13 percent lower risk of having another stroke than patients who took the previous standard therapy warfarin, with a similar risk of bleeding as a side effect and lower rates of fatal bleeding, the Leverkusen, Germany-based company said in a statement.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE